FDA Approves Subcutaneous Formulation of Alzheimer's Drug Leqembi

The U.S. Food and Drug Administration (FDA) has approved a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for weekly maintenance dosing following an 18-month IV initiation phase. This breakthrough approval opens the door for faster and simpler drug delivery and paves the way for combination therapies, a strategy that revolutionized cancer care. The subcutaneous formulation allows patients to self-administer the drug at home using an autoinjector, reducing the logistical challenges of receiving Alzheimer's treatment.

Key Takeaways:

• The FDA has approved a subcutaneous formulation of Leqembi, a treatment for Alzheimer's disease, which allows for weekly maintenance dosing following an 18-month IV initiation phase.
• The subcutaneous formulation uses an autoinjector to deliver the drug in about 15 seconds, reducing the need for hour-long intravenous infusions in hospitals or infusion sites.
• Eisai and Biogen plan to file an application for subcutaneous dosing without the need for an IV initiation phase next week.
• More than 70% of the current Alzheimer's drug pipeline focuses on non-amyloid pathways, making combination therapies a promising approach.
• Subcutaneous delivery is expected to become more common as more Alzheimer's treatments progress through development and gain approval.
• Combination therapies tailored to each patient based on their individual biomarker profiles are seen as the future of Alzheimer's care.
• Dr. Howard Fillit, Co-Founder and Chief Science Officer at the Alzheimer's Drug Discovery Foundation (ADDF), emphasized that subcutaneous delivery is a crucial step toward making Leqembi more accessible for patients and represents the first step towards the day when patients can bypass infusions altogether.

Statistics:

• More than 70% of the current Alzheimer's drug pipeline focuses on non-amyloid pathways.
• The majority of Alzheimer's treatments currently require intravenous infusions, which can take several hours.
• Subcutaneous delivery using an autoinjector reduces treatment time to about 15 seconds.
• The ADDF's focus on combination therapies tailored to each patient's individual biomarker profiles is seen as a promising approach to Alzheimer's care.
• Over 6 million people in the United States are living with Alzheimer's disease.

Sources:

• "VerticalNews" (2025 SEP 18). "FDA Approves Subcutaneous Formulation of Leqembi."
• "Eisai and Biogen. (2025). Press Release: Eisai and Biogen Plan to File Application for Subcutaneous Dosing of Leqembi Without IV Initiation Phase."